George Wilding

George Wilding, MD, Chief Medical Officer. Dr. Wilding is an expert on genitourinary cancers, particularly prostate cancer and new prostate cancer drug development. He has served as Vice President and Deputy Chief Academic Officer, Clinical and Interdisciplinary Research; Professor, Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, and as Director of Cancer Center and Head of Hematology-Oncology Division at the University of Wisconsin Carbone Comprehensive Cancer Center.

John Crown, MD, MBA, Medical Advisor. Dr. Crown, a leading medical oncologist with special expertise in breast cancer, holds Thomas Baldwin Chair in Cancer Research, Dublin City University, and is Newman Clinical Research Professor, University College Dublin. Founder of Ireland’s first national cancer treatment research group, which includes 95% of medical oncologists in Ireland and has recruited over 3,000 patients on 52 clinical trials. Dr. Crown was a Senator of Ireland till 2016.

Mark Wentland, Ph.D., Medicinal Chemistry Advisor. Dr. Wentland is Professor Emeritus at Rensselaer Polytechnic Institute. Prior to his tenure at Rensselaer, Dr. Wentlland conducted drug discovery research at Sterling Winthrop and his last position was Sterling Winthrop Fellow and Oncology Discovery Co-Chairman. Dr. Wentland has led efforts resulting in the discovery of nine drug candidates, six of which have been advanced to clinical trials.